Navigation Links
New Research Suggests That Acthar Reduces Proteinuria in Idiopathic Membranous Nephropathy In Part Through Suppression of Anti-PLA2R Antibodies
Date:11/10/2011

PHILADELPHIA, Nov. 10, 2011 /PRNewswire/ -- On November 10 at the American Society of Nephrology 44th Annual Meeting, Boston University Assistant Professor of Medicine Laurence H. Beck, Jr., M.D., Ph.D. will present results from a study which found that H.P. Acthar® Gel may induce a remission of proteinuria in patients with idiopathic membranous nephropathy (iMN) by suppressing production of antibodies to the phospholipase A2 receptor (PLA2R).  iMN is a common cause of nephrotic syndrome in adults.  Nephrotic syndrome is a known risk factor for progression to end-stage renal disease (ESRD).

"A high proportion of patients with idiopathic membranous nephropathy have circulating anti-PLA2R antibodies.  These antibodies attack a key protein located on the podocyte cells, which are found within the kidney and are directly involved in renal filtration," said Dr. Beck.  "We believe that anti-PLA2R antibodies are an important therapeutic target in the treatment of this form of chronic kidney disease.  The results of this study indicate that there appears to be a direct beneficial effect of Acthar on the immune system in patients with idiopathic membranous nephropathy."

Overall, the study included 14 patients with iMN from 2 pilot studies (Mayo Clinic and Columbia University Medical Center).  Patients were treated with Acthar for 6 months. In the study, 12 of 14 patients (86%) were anti-PLA2R positive at baseline.  All 12 patients with a baseline anti-PLA2R level experienced a reduction in anti-PLA2R by 6 months, with the complete disappearance of anti-PLA2R in 5 patients.  There were 5 patients with partial remission of proteinuria at 6 months.  Two additional patients with undetectable baseline anti-PLA2R serum levels did achieve clinical remission of proteinuria.  

"These findings provide a major step forward in the understanding of how patients with nephrotic syndrome due to idiopathic membranous nephropathy may benefit from Acthar treatment," said Steve Cartt, Executive Vice President and Chief Business Officer of Questcor Pharmaceuticals, Inc. "These data indicate that Acthar appears to work, at least in part, through an immune-modulating effect that can help restore kidney function in these patients.  We look forward to supporting further research in this area."

Nephrotic syndrome results from damage to the kidney glomeruli, tiny blood vessels that filter wastes and excess water from the blood and send them to the bladder as urine. It is characterized by excessive loss of protein in the urine, a condition known as proteinuria. This can be caused by a number of underlying diseases and disorders, including iMN, primary focal segmental glomerular sclerosis (FSGS) and other conditions. Based on epidemiology data and extensive market research with nephrologists, Questcor estimates that there are approximately 8,000 patients in the US with nephrotic syndrome due to iMN, and a similar number due to primary FSGS. There are also a number of other less common causes as well. Patients suffering from these types of idiopathic nephrotic syndrome often progress to ESRD if their kidney disease is not appropriately treated or if they do not respond adequately to treatment. According to ASN estimates, more than 500,000 patients in the US suffer from ESRD and this figure is expected to grow by 50% over the next 20 years. There are a number of disorders of the kidney that can result in ESRD and more than 100,000 new ESRD cases are diagnosed annually in the US.  Dialysis and kidney transplant are the only treatment alternatives for patients with ESRD.

A brief abstract containing a summary of the study findings was submitted and accepted by ASN and is currently available for viewing at: www.asn-online.org.  Dr. Beck's oral presentation on November 10 will provide an expanded set of data compared to that published in the abstract.

About H.P. Acthar® Gel

H.P. Acthar® Gel is a natural adrenocorticotropic hormone (ACTH) designed to provide a prolonged release after intramuscular or subcutaneous injection. Acthar is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders. For more information, please visit www.acthar.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor markets H.P. Acthar® Gel (repository corticotropin injection), which is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders.  The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Millar Instruments, Inc. and Telemetry Research Ltd Merge
2. Transparency Market Research: The North America and Europe Minimally Invasive Prostate Cancer Surgery Market is Booming: Expected to Attain a Market Size of USD 24.9 Billion by 2016
3. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
4. Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
5. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
6. Critical Alerts For Barrick Gold, Molycorp, Lockheed Martin, Teva Pharmaceutical, and Tenaris Released By Seven Summits Research
7. Kensey Nash Corporation Receives $1.9m NIH Grant for Tendon Product Research
8. Caliper Launches New Platform for Drug Safety Prediction and Oncology Research
9. JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development
10. Anaheim to Host Worlds Largest Gathering on Cystic Fibrosis Research and Care
11. Renal Research Institute Announces Scientific Presentations at the American Society of Nephrology Kidney Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... , January 16, 2017 Der ... Kollagenprodukten für die Regeneration des menschlichen Gewebes, gibt die ... mit sofortiger Wirkung bekannt. ... Bill Allan ... Er bekleidete eine Reihe von Geschäftsführer- und anderen Führungspositionen ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... , Jan. 13, 2017 Wichita Laser ... cutting-edge laser treatments to Wichita, Kansas ... provides advanced treatments for skin rejuvenation, getting rid of ... lesions and vascular lesions. "Since being in ... in Wichita for laser tattoo ...
Breaking Medicine Technology:
(Date:1/13/2017)... ... 13, 2017 , ... People with type 2 diabetes know ... easy as checking the nutrition label on foods for grams of sugar. But ... sugar-free, proteins can influence — either positively or negatively — insulin secretion and ...
(Date:1/13/2017)... ... January 13, 2017 , ... A January 10 article ... 2017 according to the publication, with an emphasis on some new techniques that the ... F.A.C.S., who is known more casually to his patients and colleagues as Dr. J, ...
(Date:1/13/2017)... ... , ... With the increasing public preference for chemical-free personal ... alternatives for customers who have grown more conscious about maintaining their health and ... charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s decision ...
(Date:1/13/2017)... ... 2017 , ... An inventor from Virginia Beach, Va., is always on the ... diversify my outfits, so he decided to design something that enhances the look of ... of a belt to allow for quick, easy changing of its look. This not ...
(Date:1/13/2017)... ... , ... "We wanted to create a design for orthodontic appliances that would ... Virginia Beach, Va. , They created a prototype for the patent-pending BRACE FACERS to ... to be customized to suit personal tastes. They can be used to create custom ...
Breaking Medicine News(10 mins):